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Human heme oxygenase-1 (hHO-1) catalyzes the O2-
dependent oxidation of heme to biliverdin, CO, and free
iron. Previous work indicated that electrophilic addi-
tion of the terminal oxygen of the ferric hydroperoxo
complex to the -meso-carbon gives 5-hydroxyheme.
Earlier efforts to block this reaction with a 5-methyl
substituent failed, as the reaction still gave biliverdin
IX. Surprisingly, a 15-methyl substituent caused exclu-
sive cleavage at the -meso- rather than at the normal,
unsubstituted -meso-carbon. No CO was formed in
these reactions, but the fragment cleaved from the por-
phyrin eluded identification. We report here that hHO-1
cleaves 5-phenylheme to biliverdin IX and oxidizes 15-
phenylheme at the -meso position to give 10-phenyl-
biliverdin IX. The fragment extruded in the oxidation
of 5-phenylheme is benzoic acid, one oxygen of which
comes from O2 and the other from water. The 2.29- and
2.11-Å crystal structures of the hHO-1 complexes with 1-
and 15-phenylheme, respectively, show clear electron
density for both the 5- and 15-phenyl rings in both mol-
ecules of the asymmetric unit. The overall structure of
15-phenylheme-hHO-1 is similar to that of heme-hHO-1
except for small changes in distal residues 141–150 and
in the proximal Lys18 and Lys22. In the 5-phenylheme-
hHO-1 structure, the phenyl-substituted heme occupies
the same position as heme in the heme-HO-1 complex
but the 5-phenyl substituent disrupts the rigid hydro-
phobic wall of residues Met34, Phe214, and residues
26–42 near the -meso carbon. The results provide inde-
pendent support for an electrophilic oxidation mecha-
nism and support a role for stereochemical control of
the reaction regiospecificity.
Heme1 oxygenase, the rate-limiting enzyme in the heme
degradation pathway, oxidizes heme to biliverdin, carbon mon-
oxide, and free iron (1) (Fig. 1). In humans and other mammals,
the heme is cleaved exclusively at the -meso position to give
biliverdin IX. The biliverdin then is reduced to bilirubin by
biliverdin reductase before it is conjugated with glucuronic acid
and excreted in the bile (2). Bilirubin is a powerful physiolog-
ical antioxidant (3), but is neurotoxic at the high concentrations
found in Criggler Najar patients and neonatal jaundice (4). CO,
the second product of the reaction, is a gaseous messenger
molecule that is thought to be involved in apoptosis (5), athero-
sclerosis (6), psoriasis (7), vascular constriction (8), cellular
protection (9), and chronic renal inflammation (10). Finally, the
ferrous iron released by heme oxygenase is normally recycled
and serves as the major source of this metal for hemoglobin and
other hemoprotein synthesis, as only 1–3% of the iron utilized
daily in the synthesis of red blood cells is obtained from the diet
(11). Thus, in addition to its other functions, heme oxygenase
plays a vital role in maintaining iron homeostasis.
In mammals, there are three heme oxygenase isoforms,
namely HO-1, HO-2, and HO-3. HO-1 is inducible and present in
highest concentration in spleen and liver. It is a stress protein
also known as heat shock protein 32 that has been extensively
studied because it is induced by a variety of agents, including
heme, metals, hormones, oxidizing agents, and drugs (4, 12).
Recently it was reported that HO-1 can prevent the inflamma-
tory responses caused by adenovirus vectors in gene therapy (13).
It is also a remarkably protective gene against allograft rejection
(14, 15). HO-2 is constitutive and is found in highest concentra-
tion in the brain and testes. It may be involved in signaling
pathways that involve CO and has been suggested to act as a
nitric oxide sink (16), although this latter role remains contro-
versial. HO-3 is also expressed constitutively, but it is a poor
catalyst, and its role, if any, is unclear (17).
The mammalian heme oxygenases are membrane bound.
However, a truncated human HO-1 construct (265 amino acids,
hHO-1) lacking the 23 C-terminal amino acids is fully active
and is water soluble (18). The successful expression of this
truncated hHO-1 in Escherichia coli has greatly facilitated the
molecular level characterization of hHO-1.
The mechanism of heme oxidation by heme oxygenase has
been partially elucidated (19). Heme is converted to biliverdin
IX via two observable intermediates, 5-hydroxyheme and
-verdoheme (Fig. 1). Oxidation of heme to 5-hydroxyheme and
of verdoheme to iron biliverdin requires NADPH-P450 reduc-
tase and O2. The intervening step in which 5-hydroxyheme is
converted to verdoheme only requires O2 and results in the
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release of CO. The degradation of heme by heme oxygenase is
highly regiospecific. In mammals, heme is exclusively cleaved
at the -meso position to give biliverdin IX (20, 21). However,
the heme oxygenase from Pseudomonas aeruginosa oxidizes
heme to biliverdin IX and IX (22).
Torpey et al. (23) attempted in 1996 to use 5-methylmeso-
heme to block 5-hydroxylation and thus to inhibit the heme
oxygenase reaction. Surprisingly, this compound was itself ox-
idized to biliverdin IX, albeit without the formation of CO.
Equally surprising was the finding that 15-methylmesoheme
was exclusively cleaved at the  position despite the presence of
the normally oxidized, unsubstituted  position. Unfortunately
it was not possible in these earlier studies to identify the
product containing the methyl group and the - or -meso-
carbon atom. Nevertheless, the fact that CO was not formed
clearly established that this unexpected oxidation did not
involve initial removal of the methyl group from the meso-
methylheme to give heme itself, which then underwent normal
cleavage.
To further characterize the mechanism governing the degra-
dation of the meso-substituted heme, we have now examined
the hHO-1-catalyzed oxidation of the 5- and 15-phenylhemes
(Fig. 2). A phenyl substituent was employed for these studies
because its chromophore would facilitate identification and
isolation of the fragment containing the meso-substituent and
the meso-carbon atom. This assumes, of course, that the phe-
nyl-substituted hemes are bound and are oxidized by hHO-1. In
fact, we report here that 5-phenylheme is oxidized at the
-meso position to give biliverdin IX with the concomitant
release of benzoic acid. In contrast, unlike 15-methylheme,
15-phenylheme is exclusively cleaved at the normal -meso
position. The crystal structures of the 5- and 15-phenylheme
complexes with hHO-1 have also been determined to clarify the
structural perturbations caused by the phenyl substituent. The
results clarify the mechanism of the heme cleavage and
the origin of the reaction regiospecificity.
EXPERIMENTAL PROCEDURES
Materials—5-Phenylheme, 15-phenylheme, and the biliverdin iso-
mers derived from the dimethyl esters of 5-phenylheme and 15-phenyl-
heme (Fig. 2) were prepared as reported previously (24–26). The dim-
ethyl-esterified biliverdin isomers were generated by published
procedures (27). 18O2 and H2
18O were from ICON Isotopes (Summit,
NJ). Ampicillin, NADPH, Mb, sodium ascorbate, trifluoroacetic acid,
and sodium dithionite were purchased from Sigma or Aldrich. Quater-
nary ammonium cellulose (QA52) was from Whatman Inc. BL21 (DE3)
plysS-competent cells were obtained from Stratagene (La Jolla, CA).
Methanol (HPLC grade) was from Fisher Scientific, the YMCTM
ODS-AQ C18 column (S-5, 120 Å, 4.6  250 mm) was from Walters
Corp., and the Sephadex G-50 quick spin column was from Roche
Applied Science.
Enzymes—A truncated human heme oxygenase 1 (hHO-1) retaining
amino acids 1–265 but lacking the 23 C-terminal amino acids was used
in this study (18). Expression and purification were carried out as
reported previously except that QA52 resin was used instead of the
Q-Sepharose fast flow resin from Amersham Biosciences (28). The apo-
hHO-1 was combined with excess heme, 5-phenylheme, or 15-phenyl-
heme. The reconstituted hHO-1 (heme-hHO-1, 5-hHO-1, 15-hHO-1,
respectively) was purified by passage through an Amersham Bio-
sciences PD-10 desalting column pre-equilibrated with 0.1 M potassium
phosphate buffer, pH 7.4 (defined here as the standard buffer). Human
P450 reductase and rat biliverdin reductase were expressed and puri-
fied by published procedures (29–31). Superoxide dismutase and bovine
liver catalase were from Sigma.
UV-visible Spectra of Heme-hHO-1, 5-hHO-1, and 15-hHO-1—The
spectra were recorded in standard buffer at room temperature on a
Cary Varian model 1E spectrophotometer.
Spectrophotometric Monitoring of Bilirubin Formation Using P450
Reductase and Biliverdin Reductase—The reaction mixture contained 6
g of heme-hHO-1, 4 M rat biliverdin reductase, 0.4 M P450 reduc-
tase, and 30 M heme in a final reaction volume of 100 l. Bilirubin
formation was initiated by the addition of NADPH (400 M). The for-
mation of bilirubin was monitored at 468 nm at 30-s intervals. For
5-phenylheme, the reaction mixture contained 5-hHO-1 and 5-phenyl-
heme, and for 15-phenylheme, 15-hHO-1 and 15-phenylheme. All the
reactions were performed at room temperature in standard buffer.
Spectrophotometric Monitoring of Fe(III) Biliverdin Formation Using
Sodium Ascorbate—Heme-hHO-1, 5-hHO-1, or 15-hHO-1 (10 M) was
incubated at room temperature with sodium ascorbate (3 mM) in 200 l
of standard buffer for 1.5 h. The solution was then passed through a
Sephadex G-50 quick spin column pre-equilibrated with standard
buffer, and the UV-visible spectrum was recorded.
CO Formation Assay Using Horse Deoxymyoglobin as a CO Trap—
Heme-hHO-1, 5-hHO-1, or 15-hHO-1 (10 M) in 1 ml of standard buffer
was incubated in air tight vials at room temperature for 10 min with
NADPH (400 M) and P450 reductase (1 M). Fe(II) Mb (50 l, 83 M)
was then added to the solution via a syringe to a final concentration of
4 M. The solution was shaken well, and the UV-visible spectrum was
recorded. The Fe(II) Mb (83 M) was freshly prepared by adding sodium
dithionite solution (70 l, 1 M) to a metMb solution (350 l, 100 M)
without further purification.
HPLC Analysis of Biliverdin Isomers—Heme-hHO-1, 5-hHO-1, or
15-hHO-1 (45 nmol) was incubated with NADPH (3.4 mol) and P450
reductase (4.5 nmol) in standard buffer for 2 h at room temperature.
The reaction volume was 650 l. The reaction mixture turned reddish in
the case of 5-hHO-1 and green in the case of heme-hHO-1 and 15-
hHO-1. Methanol was added to a final concentration of 60%, and the
resulting mixture was subjected to centrifugation. To the supernatant
was added 1 drop of concentrated HCl plus a few drops of acetic acid
before the solution was extracted with an equal volume of CH2Cl2. The
organic phase was washed with an equal volume of water and was then
evaporated under a stream of air. The residual products were dissolved
in methanol/5% H2SO4 (v/v), and the mixture was allowed to stand at
room temperature for at least 16 h. The resulting dimethyl-esterified
products were extracted with CHCl3 and washed with water. The or-
ganic phase was dried under a stream of air, and the residue was
dissolved in methanol. Before loading onto a YMCTM ODS-AQ C18
column, the concentration of methanol was adjusted to 60–70%.
Coupled oxidation with sodium ascorbate was carried out by incubating
each of the complexes, i.e. heme-hHO-1, 15-hHO-1, or 5-hHO-1 (45 nmol),
with sodium ascorbate (13 mg) in standard buffer for 2 h at room tem-
perature. The reaction volume was 320 l. The degradation products
went through the same procedures as above for HPLC analysis.
The dimethyl-esterified products were loaded onto a YMCTM
FIG. 1. Scheme of the oxidation of heme catalyzed by heme
oxygenase. The - (5-), -, - (15-), and -meso positions of the heme
are labeled.
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ODS-AQ C18 column. HPLC was done with a Varian 1090 solvent
delivery system and a Hewlett-Packard 1040A detector at room tem-
perature. Solvents A and B were H2O and methanol, respectively. The
running conditions were the following: flow rate, 1.0 ml/min; 30% B for
5 min, 30–70% B in 0.1 min, 70–95% B in 25 min, 95% B for 10 min,
95–30% B in 5 min, and finally 30% B for 20 min. The eluent was
monitored at 380 nm and referenced against 598 nm.
HPLC Analysis of the Fragment Containing the -Carbon and Phenyl
Group—The heme-hHO-1, 5-hHO-1, or 15-hHO-1 complex (7 nmol)
was incubated with NADPH (400 nmol) and P450 reductase (0.6 nmol)
in standard buffer at room temperature for at least 1 h. Methanol and
trichloroacetic acid were then added to the reaction solution to final
concentrations of 60 and 10%, respectively. The resulting solution stood
on ice for at least 30 min. The precipitate was removed by centrifuga-
tion, and the supernatant was loaded onto a YMC ODS-AQTM C18
column. HPLC was carried out at room temperature with a Varian 1090
solvent delivery system and a Hewlett-Packard 1040A detector, using
the following conditions (solution A, H2O/0.05% trifluoroacetic acid;
solution B, methanol/0.1% trifluoroacetic acid, flow rate, 1.0 ml/min):
10% B for 5 min, 10–30% B in 0.1 min, 30–55% B in 25 min, 55–95% B
in 5 min, 95% B for 5 min, 95–10% B in 0.1 min, and 10% B for 15 min.
Benzoic acid and benzaldehyde standards were dissolved in a mixture of
standard buffer, 60% methanol, 10% trichloroacetic acid. The eluent
was monitored at 230 and 254 nm and was referenced against the
absorption at 598 nm. Benzoic acid has a maximum absorption at 230
nm and benzaldehyde at 254 nm
The incubation of 5-hHO-1 with P450 reductase and NADPH was
also performed in the presence of superoxide dismutase and catalase.
The reaction went through the same experimental protocol as
above.
Mass Spectrometric Analysis of the Species Containing the -Carbon
and Phenyl Group—5-hHO-1 or heme-hHO-1 (29 nmol) was incubated
with P450 reductase (2.9 nmol) and NADPH (1.8 mol) at room tem-
perature for 2 h. The final reaction volume was 116 l. The reaction
mixture was injected into a Waters Micromass ZQ Mass Spectrometer.
The equipment was run under electrospray ionization in negative ion
mode (ES mode), and the mass spectra were analyzed using the
MassLynxTM 3.5 program. The mass spectrum of 5-hHO-1 alone was
also obtained as a control.
Origin of the Oxygen Atoms in the Benzoic Acid from Oxidation of
5-Phenylheme—Oxidation of 5-phenylheme by hHO-1 was carried out
in either 18O2 or H2
18O. For the reaction in 18O2, 5-hHO-1 (10 l, 2.95
mM) and P450 reductase (5.8 l, 274 M) were added to 100 l of
standard buffer on the bottom of a two-necked flask. One drop of
NADPH (30 l, 0.1 M) was spotted separately on the inner wall. Air was
removed by three cycles of purging with argon gas and placing under
vacuum. NADPH was then mixed with the enzymes by shaking the
flask slightly followed by introduction of 18O2 into the flask. The mix-
ture was allowed to stand at room temperature for 0.5 h before it was
passed through an ultracentrifugal filter device (10,000 molecular
weight cutoff, Millipor Amicon®) to remove the protein before analysis
by liquid chromatography-mass spectrometry (LC-MS). For the reaction
in H2
18O, a mixture of 5-hHO-1 (5.4 l, 2.95 mM) and P450 reductase
(2.9 l, 274 M) was lyophilized for 1 h, dissolved in 50 l of H2
18O, and
relyophilized for 1 h. The residue was dissolved in 100 l of H2
18O and
was then mixed with 4 l of NADPH (1 M in H2
18O). The mixture was
allowed to stand at room temperature for 0.5 h before it was passed
through the ultracentrifugal filter device to remove the protein before
analysis by LC-MS.
LC-MS was performed on a Waters Micromass ZQ coupled to a
Waters Alliance HPLC system (2695 Separations Module, Waters
2487 Dual  Absorbance detector) employing an Xterra® MS C18
column (2.1  50 mm, 3.5 m). For the chromatography, solvent A
was 0.1% ammonium hydroxide in water and solvent B was methanol.
The column was eluted with 5% solvent B (95% solvent A) at a flow
rate of 0.2 ml/min. The eluent was monitored at 230 nm. The MS
settings were: mode, ES; capillary voltage, 2.9 kv; cone voltage, 20 v;
source temperature, 130 °C; desolvation temperature, 300 °C. Masses
FIG. 2. Left, structures of 5-phenylheme and the phenyl-substituted biliverdin IX, IX, and IX derived by coupled oxidation of the dimethyl
ester of 5-phenylheme. Right, structures of 15-phenylheme and the phenyl-substituted biliverdin IX, IX, and IX isomers obtained by coupled
oxidation of the dimethyl ester of 15-phenylheme (24–26). The electronic absorption maximum of each compound in CH2Cl2 is indicated.
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115–200 were scanned with a scan time of 0.2 s. The control experi-
ment was performed by incubation of 5-hHO-1 (29 nmol) with P450
reductase (2.9 nmol) and NADPH (1.8 mol) in 100 l of standard
buffer for 0.5 h.
Crystallography—Crystals of 15-hHO-1 and 5-hHO-1 were grown
under slightly different conditions than those described previously (32,
33). Crystals were obtained using the hanging-drop vapor diffusion
method with a well solution of 2.0–1.5 M ammonium sulfate, 100 mM
HEPES, pH 7.5, 0.9% 1,6-hexanediol, and 10–30% Jeffamine ED-600.
Drops consisted of protein stock (5 l) at 65 mg ml1 in 100 mM
potassium phosphate, pH 7.4, mixed with well solution (5 l). Crys-
tals were grown at room temperature, and one round of touch seeding
using crushed wild-type crystals was necessary to initiate 15-hHO-1
crystal growth. For 5-hHO-1 macro seeding had to be used to obtain
crystals of suitable size for data collection. For cryogenic data collec-
tion D-()-trehalose was used as the cryoprotectant. Cryogenic data
collection involved a seven-step transfer to artificial precipitant so-
lution with increased D-()-trehalose concentration up to 35% (w/v).
Heme-hHO-1 and 5-hHO-1 crystals belong to the monoclinic space
group, P21, whereas 15-hHO-1 crystals belong to the orthorhombic
space group, P212121. Cell dimensions of all the crystal forms are
listed in Table I. Data were collected using an R-AXIS IV imaging
plate detector equipped with a rotating copper anode x-ray generator
with Osmic optics (Rigaku). For this data set, a 180° scan using 1°
frames was collected. Crystals were maintained at 160 °C in a
stream of nitrogen (Crystal Logic, Los Angeles). Data were reduced
using HKL 2000 (34), and rejections were performed with ENDHKL
(Louis Sanchez, California Institute of Technology) in conjunction
with SCALEPACK.
Both the 15-hHO-1 and 5-hHO-1 structures were determined by the
method of molecular replacement using AmoRe (35). A monomer of the
human heme-hHO-1 crystal structure (Protein Data Bank accession
number 1N45) (36), with the heme and waters removed, was used as the
probe with searches carried out at 5 Å in either P212121 (15-hHO-1) or
P21 (5-hHO-1) space group. The best cross-rotation and translation
function solutions were rigid body-refined and fixed in place followed by
a search for the remaining molecule in the asymmetric unit. A total of
two solutions was found per structure, corresponding to the expected
two monomers per asymmetric unit. The final R-factors were 38 and
42% with correlation coefficients of 63 and 52% for 15-hHO-1 and
5-hHO-1, respectively. The structures were further refined in CNS (37).
The structures were initially refined by simulated annealing, followed
by a few cycles of conjugate gradient minimization and water picking.
Finally, temperature factors were refined. No restraints for non-crys-
tallographic symmetry were applied. The program O (38) was used for
further adjustment and modeling of protein atoms, ligands, and water
molecules. Backbone geometry was checked with PROCHECK (39), and
none of the residues were in the disallowed region.
Data collection and refinement statistics are summarized in Table I,
and the Protein Data Bank coordinates have been deposited in the
Protein Data Bank (accession codes 1S13 and 1T5P).
FIG. 3. UV-vis spectra of the complexes of hHO-1 with heme (heme-hHO-1), 5-phenylheme (5-hHO-1), and 15-phenylheme (15-hHO-
1). The position of the Soret absorption maximum is indicated. The insets show the HPLC traces of heme, 5-phenylheme, and 15-phenylheme,
respectively.
FIG. 4. Spectrophotometric monitoring of bilirubin formation in the presence of P450 reductase and biliverdin reductase. The
spectra were monitored at 30-s intervals for 3 min. Bilirubin has an absorption maximum at 468 nm. The arrows indicate the direction of the
time-dependent spectral change.
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RESULTS
UV-visible Spectra of Heme-hHO-1, 5-hHO-1, and 15-hHO-1—
Apo-hHO-1 was combined with heme, 5-phenylheme, or 15-
phenylheme and the resulting reconstituted heme oxygenase
was immediately purified. The UV-visible spectra of the three
reconstituted complexes (Fig. 3) show that both heme-hHO-1
and 5-hHO-1 have a Soret absorption maximum at 404 nm,
whereas the maximum of the 15-hHO-1 complex is at 408 nm.
As the Soret maxima in phosphate buffer at pH 7.4 of free
heme, 5-phenylheme, and 15-phenylheme are at 364, 388, and
388 nm, respectively, there is a differential shift in the Soret
maxima when they are bound in the hHO-1 active site. The
shift for 5-phenylheme is 4 nm less than for 15-phenylheme,
and both of the phenylhemes undergo a smaller shift than
heme itself. These results confirm that the meso-phenyl hemes
are able to bind to hHO-1 and suggest that their binding causes
some perturbation of the active site.
Bilirubin and CO Formation Using P450 Reductase and
Biliverdin Reductase—The normal degradation of heme by
hHO-1 gives biliverdin IX and CO. The electrons required for
the degradation of heme are provided by NADPH via P450
reductase. Biliverdin IX is then reduced to bilirubin IX by
biliverdin reductase. As shown in Fig. 4A, these combined
reactions cause a decrease in the heme Soret absorption at 404
nm and the accumulation of bilirubin with an absorption max-
imum at 468 nm. For 5-phenylheme, the reaction gives very
similar UV-visible spectral changes (Fig. 4B), i.e. a decrease in
the Soret band intensity associated with an increase in absorp-
tion at 468 nm. For 15-phenylheme, however, the UV-visible
spectral changes are different in that the absorption of both the
Soret band at 408 nm and at 468 nm decreases (Fig. 4C).
The high affinity of Fe(II) Mb for CO has been used previ-
ously to detect CO formation in the oxidation of heme by hHO-1
(23), as the Soret absorption maximum at 434 nm of Fe(II) Mb
shifts to 422 nm when CO is bound. Furthermore, the extinc-
tion coefficient of Fe(II)-CO Mb (207 mM1 cm1) is 2-fold
higher than that of Fe(II) Mb (121 mM1 cm1) (40), which
FIG. 5. Fe(III) biliverdin formation under coupled oxidation
conditions. The complex (heme-hHO-1, 5-hHO-1, or 15-hHO-1) was
incubated with sodium ascorbate for 2 h. The solution was then passed
through a G-50 quick spin column, and the UV-visible spectrum was
recorded.
FIG. 6. HPLC analysis of the biliverdin dimethyl esters isolated from the reactions of the heme-hHO-1 (A), 5-hHO-1 (B), and 15-hHO-1 (C)
complexes supported by NADPH-P450 reductase. A mixture of the standards obtained by coupled oxidation of 5-phenylheme and 15-phenylheme
is shown in D, along with the assignments of the peaks based on the NMR structural analysis (24–26). The peaks are labeled as follows: -5,
15-phenylbiliverdin IX; -5, 10-phenylbiliverdin IX; -5, 5-phenylbiliverdin IX; -15, 10-phenylbiliverdin IX; -15, 5-phenylbiliverdin IX;
-15, 15-phenylbiliverdin IX.
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enhances the sensitivity of the assay. The reactions of heme-
hHO-1, 5-hHO-1, or 15-hHO-1 with P450 reductase and
NADPH were carried out in sealed vials. After completion of
the reactions, Fe(II) Mb was injected into the vials. The
Fe(II)-CO Mb complex was immediately formed if it was pres-
ent. To make sure that all the Fe(II) Mb that was added bound
CO, which improved the accuracy of the assay, a substoichio-
metric amount (0.4 equivalent) of Fe(II) Mb was used. The
results of this assay indicate that both heme-hHO-1 and 15-
hHO-1 produce CO (data not shown), whereas 5-hHO-1 does
not. In view of the spectrophotometric demonstration of biliru-
bin formation (Fig. 4), it is clear that hHO-1 catalyzes the
degradation of the two phenyl-substituted hemes. 5-Phenyl-
heme is cleaved at the  position, as no CO is released, whereas
15-phenylheme is cleaved at a position other than the -meso
position, probably at the normal -meso position, resulting in
the formation of CO.
Fe(III) Biliverdin Formation Using Sodium Ascorbate—The
degradation of heme by hHO-1 to Fe(III) biliverdin can be
supported by the surrogate electron donor sodium ascorbate.
Fig. 5 shows that incubation of 5-hHO-1 with ascorbate gives a
spectrum with a broad absorption at around 380 nm similar to
that obtained by coupled oxidation of heme-hHO-1. This spec-
trum corresponds to that of the hHO-1 complex of ferric biliv-
erdin IX. However, the spectrum obtained on coupled oxida-
tion of 15-hHO-1 has a maximum of absorption at 400 nm and
is quite different. This result is consistent with the already
described bilirubin and CO formation studies, all of which
suggest that 5-phenylheme is degraded enzymatically by
hHO-1 without CO release, probably to biliverdin IX. In con-
trast, the oxidation of 15-phenylheme by hHO-1 yields CO and
one or more products thought to be phenyl-substituted
biliverdins.
HPLC Analysis of Biliverdin Isomers—To simplify the iden-
tification of biliverdin isomers by HPLC, all the biliverdin
isomers produced by coupled oxidation of heme, 5-phenylheme,
and 15-phenylheme were converted to the corresponding di-
methyl esters. The coupled oxidation was carried out in the
absence of hHO-1 and thus gave mixtures of the isomers ex-
pected from cleavage at each of the three non-phenyl substi-
tuted meso positions in each molecule (Fig. 2) (24–26). As
shown in Fig. 6A, incubation of heme-hHO-1 with NADPH-
P450 reductase gives a single HPLC peak that corresponds to
the dimethyl ester of biliverdin IX (max  375 nm, retention
time  26.9 min). The HPLC conditions employed here (see
“Experimental Procedures”) separate the isomeric biliverdin
dimethyl esters very well except for the dimethyl esters of
5-phenylbiliverdin IX and 15-phenylbiliverdin IX, both of
which have a retention time of 31.0 min (Fig. 6D). Incubation
of 5-hHO-1 with NADPH-P450 reductase produces a species
with exactly the same retention time and spectrum as the
dimethyl ester of biliverdin IX (Fig. 6B). In the case of 15-
hHO-1, the product has a retention time (28.6 min) and spec-
trum (max  393 nm) that correspond to the dimethyl ester of
10-phenylbiliverdin IX (Fig. 6C). It is thus clear that both
phenyl-substituted hemes are cleaved at the  position. A mi-
nor product peak is also observed in the HPLC traces for
5-hHO-1 and 15-hHO-1 (Fig. 6, B and C), but these peaks do
not co-elute with the dimethyl esters of the -, -, -, or -biliv-
erdin isomers (data not shown). The identities of these minor
products are therefore obscure, although they may derive from
the minor impurities present in the original 5- and 15-phenyl-
heme samples (Fig. 3).
The same products as were obtained in the reactions sup-
ported by P450 reductase are obtained in the ascorbate-sup-
ported degradation of heme and the phenyl-substituted com-
pounds by hHO-1, i.e. biliverdin IX and 10-phenylbiliverdin
IX (data not shown). Among other things, this establishes that
the heme oxidations occurred entirely within the hHO-1 com-
plex and not in solution, as a mixture of the isomers is obtained
in solution. Interestingly, coupled oxidation with ascorbate of
the 5- and 15-phenylhemes in the absence of the enzyme re-
sults in oxidation of only the three non-substituted meso posi-
tions (Fig. 2) (25, 26). Thus, the observation that the phenyl-
substituted position of the 5-hHO-1 complex is exclusively
oxidized, whether the reaction is supported by NADPH-P450
reductase or ascorbate, clearly demonstrates that the stereo-
chemical control imposed by the enzyme overrides the inherent
higher reactivity of the unsubstituted meso positions.
Identification of the Product Containing the -meso-Carbon
and Phenyl Group—The results above clearly establish that
5-phenylheme is oxidized by hHO-1 to biliverdin IX. What,
then, is the identity of the product that contains the -meso-
carbon and the phenyl group attached to it? The most obvious
possibilities are benzaldehyde and benzoic acid, although other
products can be envisioned. Under our HPLC conditions (see
“Experimental Procedures”) authentic benzoic acid elutes at
24.4 min and benzaldehyde at 21.6 min. Not only are the two
FIG. 7. HPLC analysis of the product containing the phenyl
group and -meso-carbon. The solid line is the absorbance at 230 nm,
and the dashed line is the absorbance at 254 nm.
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molecules well separated, but benzoic acid has an absorption
maximum at 230 nm and benzaldehyde at 254 nm. The two are
therefore readily distinguished. Incubation of 5-hHO-1 with
NADPH-P450 reductase produces a peak with the same reten-
tion time and absorption spectrum as benzoic acid but no de-
tectable benzaldehyde (Fig. 7). However, as benzaldehyde is
susceptible to oxidation and could have been a precursor of the
observed benzoic acid, we repeated the experiment in the pres-
ence of superoxide dismutase and catalase. Again, only benzoic
acid was detected. As a further control, we allowed a solution of
benzaldehyde to stand at room temperature for several days
and then analyzed the solution by HPLC. No benzoic acid was
detected. These control experiments confirm that the initial
product in the reaction is benzoic acid and not benzaldehyde. In
the incubations of 15-hHO-1 with P450 reductase, a trace
amount of what appears to be benzoic acid was detected. Close
inspection of the products found in the P450 reductase-sup-
ported reaction (Fig. 6C) shows traces of products that might
correspond to biliverdin IX, but repeated analysis rules this
out. The trace amount of benzoic acid detected in Fig. 7 in the
15-hHO-1 plot therefore must derive from the impurities in the
original sample (Fig. 3), as no benzoic acid is generated in
control incubations of heme-hHO-1 with P450 reductase
(Fig. 7).
Mass spectra of the reaction mixtures from incubations of
5-hHO-1 with NADPH-P450 reductase were obtained in the
ES mode (Fig. 8). An ion of m/z 121.02, which corresponds to
the expected molecular ion of benzoic acid (molecular weight
122.04), was detected (Fig. 8A). To rule out the possibility that
the benzoic acid detected was due to contamination from any of
the three reaction constituents (5-hHO-1, P450 reductase, and
NADPH), two controls were carried out. One was to incubate
heme-hHO-1 with P450 reductase and NADPH, then to take
the mass spectrum of the reaction mixture. The second control
was to obtain the mass spectrum of 5-hHO-1 alone. No benzoic
acid was detected in these control experiments (Fig. 8, B
and C).
To identify the origin of the oxygen atoms in the benzoic acid,
the reaction of 5-hHO-1 with P450 reductase and NADPH was
performed in 18O2 and H2
18O, respectively, followed by LC-MS
analysis. For the reaction in normal water under a normal
atmosphere of air, a species with the same retention time as
authentic benzoic acid (1.9 min) and the expected mass of 121
(m/z) under ES mode was observed (Fig. 9, left). In contrast,
singly 18O-labeled benzoic acid with a mass of 123 (m/z) was
detected in the reaction performed in H2
18O. The ratio of un-
labeled and single labeled benzoic acid is about 1.0:1.3 (Fig. 9,
right). For the reaction carried out in 18O2, however, both
singly and doubly 18O-labeled benzoic acid with masses of 123
(m/z) and 125 (m/z), respectively, were observed (Fig. 9, mid-
dle). The ratio of unlabeled, singly labeled, and doubly labeled
benzoic acid is about 1.0:4.5:3.0. These results suggest that one
oxygen atom in benzoic acid comes from oxygen gas and the
other from water. Since the heme oxygenase reaction generates
water within the active site, the reaction in 18O2 can, as found,
give rise to some incorporation of a second atom of 18O through
addition of in situ generated labeled water.
15-hHO-1 and 5-hHO-1 Structures—Both 15-hHO-1 and
5-hHO-1 complexes crystallized under slightly different condi-
tions than the heme-hHO-1 complex, in that the addition of
Jeffamime ED-600 was required to obtain suitable crystals.
The final R-factors for the refined structures were 21.4 and
24.3% for 15-hHO-1 and 5-hHO-1, respectively (Table I).
Fig. 10 shows an omit electron density map of the 15-phe-
nylheme in 15-hHO-1. The phenyl group is well defined, but
only one of the heme propionates is visible. The apparently
disordered propionate was omitted from the model. The 15-
phenylheme is flatter than the heme in heme-hHO-1 and does
FIG. 9. Molecular ions region of the mass spectra of benzoic
acid isolated from a normal incubation (left) and incubations
carried out in 18O2 (middle) and H2
18O (right).
FIG. 8. Mass spectrum of the reaction mixture of 5-hHO-1  P450 reductase  NADPH (A), heme-hHO-1  P450 reductase 
NADPH (B), and 5-hHO-1 alone (C). The ion intensities for the peaks at m/z 121.02 (A), 123.90 (B), and 129.81 (C) are 1.2  106, 1.1  105, and
6.2  103, respectively. The sensitivity in B and C was set much higher than in A to determine whether any signal was present at m/z 121.
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not have a distal water ligand. The overall structures of 15-
hHO-1 and heme-hHO-1 are the same with a root mean square
deviation (r.m.s.d.) of only 0.38 Å. However, a closer analysis of
the heme active site reveals subtle differences caused by the
need to accommodate the 15-phenyl substituent (Fig. 10B).
These differences are confined to parts of the distal helix,
residues 141–150 (Fig. 10B, thick lines), and Lys18 and Lys22 of
the proximal helix (Fig. 10B). The stretch of residues in the
distal helix from residue 141 to 150 shifts1.2 Å inward (away
from the bulk solvent) in the 15-hHO-1 versus heme-hHO-1
structure. On the proximal side Lys18 and Lys22, which in
heme-hHO-1 stabilize the outer heme propionate group, move
FIG. 10. Crystal structure of 15-hHO-1. A, stereo diagram of the 2Fo  Fc omit electron density contoured at 1  around 15-phenylheme of
15-hHO1. B, stereo view comparison of the backbone atoms between heme-hHO-1 (gray) and 15-hHO-1 (black). Thick lines represent regions of
substantial change between the two sets of structures. The proximal residues Lys18 and Lys22 are also shown.
TABLE I
Data collection and refinement statistics
Values in parentheses are for the outermost shell.
15hHO-1 5h-HO-1
Protein Data Bank code 1S13 1T5P
Crystal data
Radiation source Raxis-IV Raxis-IV
Space group P212121 P21
Cell parameters (Å) and  (°) a  55.0, b  75.75 a  52.91, b  64.43
c  107.3,   90.00 c  60.47,   90.02
Data collection
Detector distance (nm) 140 140
Molecules per asymmetric unit 2 2
Resolution (Å) 2.29 2.11
Mosaicity (°) 0.67 1.1
Total observations 241,896 308,112
Unique reflections 49,102 62,102
Completeness (%) 99.9 91.8
Mean I/ 11.5 (2.1) 10.1 (2.0)
Rsym (%) 5.1 (46.7) 5.4 (49.3)
Refinement statisticsa
Rcryst 0.22 0.25
Rfree 0.25 0.29
r.m.s.d. bond lengths (Å)b 0.006 0.006
r.m.s.d. angles (°)b 1.1 1.2
Water molecules 185 109
Ramachandran angles
Most favored (%) 94.9 96.3
Additional allowed (%) 5.1 3.7
a Rcryst  (Fobs  Fcalc)/ Fobs. The Rfree is the Rcryst calculated on the 5% reflections excluded for refinement.
b r.m.s. bond and r.m.s. angle represent the root mean square deviation between the observed and ideal values.
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away in the 15-hHO-1 structure. These changes in the distal
and proximal helices are required to accommodate the heme
15-phenyl ring in 15-hHO-1. Most importantly, the orientation
of the 15-phenylheme remains unchanged, leaving the -meso
heme carbon in exactly the same position as that in the heme-
hHO-1 complex. This, together with the lack of changes in key
catalytic groups such as Asp140, explains why the 15-phenyl-
heme is hydroxylated at the same -meso carbon as the unsub-
stituted heme.
Fig. 11A shows an omit electron density map of the 5-phe-
nylheme in 5-hHO-1. As in the case of 15-hHO-1, the overall
structure of 5-phenylheme is flat, no distal water ligand is
observed, and the phenyl group points down from the heme
plane. However, in the 5-hHO-1 structure both heme propio-
nate groups are visible, and the distal helix, including key
catalytic residues such as Asp140, remains relatively un-
changed in comparison to the heme-hHO-1 structure (Fig.
11B). The major difference between the heme-hHO-1 and
5-hHO-1 structures is in the immediate vicinity of the -meso
heme carbon (Fig. 11, B and C). In the heme-hHO-1 structure
the -meso position faces a wall of hydrophobic residues includ-
ing Met34, Phe37, and Phe214 that remains unperturbed when
ligands bind or when the heme is replaced by biliverdin IX or
verdoheme (36, 41–44). However, in the 5-hHO-1 structure
electron density for Met34, Phe37, and residues 32–42 is not
visible and, hence, must be disordered. A close comparison of
the -meso carbon region between the heme-hHO-1 and
5-hHO-1 structures reveals that the 5-phenyl ring would clash
with Gln27 (Fig. 11C). As a result Gln27 and residues 28–31
must move to accommodate the 5-phenyl substituent on the
heme (Fig. 11C). In the 5-hHO-1 structure the backbone atoms
of Gln27 must flip by 180° to avoid steric clashes with the
phenyl ring. As a consequence residues 32–42 must also move
but apparently do not adopt a new fixed conformation, since
these residues now are disordered. Thus, the protein adapts to
the new phenyl group by a disordering of the interior hydro-
phobic structure, which then allows the modified heme to adopt
the same orientation as that observed in the heme HO-1 struc-
ture. This helps to explain why oxidation still occurs at the
-meso carbon.
DISCUSSION
Hydroxylation of heme to 5-hydroxyheme is the first step in
the conversion of heme to biliverdin by mammalian heme oxy-
genases. The mechanism of this reaction has been proposed to
involve electrophilic addition of the terminal oxygen in the
ferric hydroperoxo complex to the -meso-carbon, followed by
elimination of the meso-proton to give the 5-hydroxyheme prod-
uct (45). The evidence for this mechanism comes from observa-
tion of the ferric hydroperoxo complex in cryogenic experiments
(46), from the demonstration that reaction of heme-hHO-1 with
ethylhydroperoxide gives the 5-ethoxyheme product (47) and
from the observation that an electron donating meso-methyl
substituent favors, and an electron withdrawing substituent
FIG. 11. Crystal structure of
5-hHO-1. A, stereo diagram of the 2Fo 
Fc omit electron density contoured at 1 
around 5-phenylheme of 5-hHO1. B, ste-
reo view comparison of the backbone at-
oms between heme-hHO-1 (gray) and
5-hHO-1 (black). Thick lines represent re-
gions of substantial change between the
two sets of structures. C, close up stereo
view of the structural change near the
-meso carbon between heme-hHO-1
(gray) and 5-hHO-1 (black).
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disfavors, reaction at the substituted meso-carbon (23, 48).
Furthermore, mechanistic studies indicate that the meso-hy-
droxy group is critical for the second step of the reaction se-
quence, the conversion of 5-hydroxyheme to verdoheme. Thus,
EPR studies in the presence and absence of CO, used in the
experiment to trap the iron in the ferrous state, show that
electron transfer from the meso-hydroxyl reduces the iron and
produces a carbon radical that reacts with molecular oxygen to
set up the carbon-carbon bond cleavage reaction (49).
Substitution of the -meso position with a methyl or phenyl
group prevents formation of 5-hydroxyheme. This is confirmed
by the fact that the oxidation does not yield CO and therefore
does not proceed via the normal oxidation sequence (23). It is
therefore necessary to postulate an oxidation mechanism that
diverges from that for the normal oxidation but still produces
the same biliverdin product (even if not CO). The present
finding that the hHO-1-catalyzed oxidation of 5-phenylheme
yields benzoic acid (Fig. 7) narrows the possibilities for this
alternative mechanism. By inference, this result suggests that
the group eliminated in the oxidation of 5-methylheme is acetic
acid (23). The bond between the -meso-carbon and the at-
tached substituent therefore remains intact in the reaction, in
accord with the failure to form CO. Control experiments estab-
lish that the benzoic acid is the immediate product and does not
result from autoxidation of benzaldehyde. The reaction re-
quires two oxidative steps and the introduction of two oxygen
atoms, one of which is presumably the oxygen from the ferric
hydroperoxo intermediate normally involved in the reaction.
Although the mechanistic scope for the oxidation of 5-phe-
nylheme by hHO-1 is defined by the present studies, the actual
mechanism for the reaction remains elusive. It is difficult to
postulate a mechanism for the reaction that does not involve an
additional intermediate. Thus, one possibility is electrophilic
addition of the ferric hydroperoxo species to give an epoxide or,
after water addition, a diol intermediate (Fig. 12). This inter-
mediate could then be converted to biliverdin IX and benzoic
acid in a second oxidative step. Further detailed analysis of the
reaction is required to see if such an intermediate can be
detected and characterized.
The oxidation of 15-phenylheme by hHO-1 occurs at the
normal -meso position to give 10-phenylbiliverdin IX and
CO. HPLC analysis confirms that the reaction yields exclu-
sively the 10-phenylbiliverdin IX isomer expected from cleav-
age at the -meso position. In a sense, this is the least surpris-
ing site for the reaction, given that the oxidation occurs at all,
because it is the site normally oxidized by the enzyme. How-
ever, it is unexpected because our earlier work showed that the
15-methylheme was oxidized not at the normal -meso position
but at the unnatural, substituted -meso-carbon (23). To deter-
mine whether the 15-substituent perturbed the active site
structure in a manner that explained the different regiochem-
istries of 15-methyl versus 15-phenyl oxidation, we have deter-
mined the structure of the complexes of hHO-1 with both 5- and
15-phenylheme. Surprisingly, the substituted heme structure,
if anything, is flatter than that of the more distorted heme
normally bound in the hHO-1 active site (Figs. 10 and 11).
Although meso substitution is commonly associated with puck-
ering of the heme ring (50–52), AM1 calculations predict that
the porphyrin ring in 15-phenylprotoporphyrin IX will be flat,
whereas that in the 5-phenyl isomer will be distorted into a
saddle shape (24). The 15-phenyl ring, which is predicted and
found to be non-coplanar with the porphyrin ring, is accommo-
dated by a shift of residues 141–150 by 1.2 Å and by displace-
ment of Lys18 and Lys22. The shift of the helix includes residue
Asp140, which is involved in a hydrogen-bonding network that
includes the distal water residue and is thought to be involved
in activation of the iron-bound dioxygen molecule (53, 54).
These changes are associated with an increased disorder in the
position of the heme propionic acid group that normally inter-
acts with Lys18 and Lys22. As a result, the propionic acid group
FIG. 12. Scheme showing one possi-
ble mechanism for the oxidation of
5-phenylheme to biliverdin IX and
benzoic acid that accounts for the ob-
served incorporation of one oxygen
from O2 and one from H2O.
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is not seen in the electron density map.
Despite the modest structural changes, the surprising result
is that the 15-phenyl causes only a modest perturbation of the
active site. As it appears unlikely that a meso-methyl will
perturb the active site to a greater extent than a meso-phenyl,
the stereochemical difference must be controlled by other fac-
tors. A methyl substituent (0.37 to0.10) is considerably
more electron donating than a phenyl group (0.07 to 0.22)
(55), which would favor electrophilic addition to the methyl-
substituted but not phenyl-substituted position relative to the
normally oxidized unsubstituted -meso-carbon. This differ-
ence in electronic effects probably contributes to the divergent
oxidation regiochemistries observed with the meso-methyl and
meso-phenyl substituents, but we cannot rule out the possibil-
ity that subtle structural changes are important.
The changes in the distal helix observed in 15-hHO-1 do not
occur in the 5-hHO-1 structure but instead unexpectedly large
changes are observed in the vicinity of the -meso carbon (Fig.
11B). In the heme-HO-1 structure the -meso-carbon faces a
wall of hydrophobic residues, Met34, Phe37, and Phe214, which
are generally considered to be quite rigidly held in place. How-
ever, introduction of the 5-phenyl ring causes a major disrup-
tion in this hydrophobic wall. Electron density for Met34 and
Phe37 is absent, suggesting a disordering of these residues,
which most likely correlates with the 180° flip of Glu27 to avoid
collision with the 5-phenyl ring (Fig. 11C). Although residues
32–42 are disordered in the 5-hHO-1 structure, other nearby
residues (residues 26–31) are visible and clearly have moved to
accommodate the 5-phenyl ring (Fig. 11C). The ability of the
hydrophobic wall to accommodate the heme phenyl ring thus
enables the modified heme to adopt the same orientation as is
observed in the heme-hHO-1 complex. The propionates remain
oriented toward the surface, where they interact with charged
groups. That the heme-propionate interactions remain un-
changed, while the hydrophobic wall near the -meso edge
disorders indicates that the heme-propionate interactions must
be very important in properly orienting the heme. The impor-
tance of propionate-protein interactions is supported by mu-
tagenesis studies (56). Furthermore, the recently determined
crystal structure of a bacterial heme oxygenase from P. aerugi-
nosa, a HO enzyme that primarily hydroxylates the -meso-
carbon, shows that the novel regioselectivity is due to rotation
of the heme by 100° (57). The rotation of the heme was
primarily due the stabilizing contacts of the heme propionates
in one orientation versus the other. The 5-hHO-1 structure
provides further evidence that heme propionate-protein inter-
actions play a key role in orienting the heme for proper regi-
oselective hydroxylation.
The present results have identified the fragment lost from
5-phenylheme as benzoic acid, which implicates the existence
of at least one additional reaction intermediate in the unusual
oxidation of 5-substituted hemes by heme oxygenase. Struc-
tural data on the enzyme complexes of 5-phenylheme and 15-
phenylheme shows that the 15-phenyl is readily accommodated
with only minor structural perturbation of the active site,
whereas one wall of the active site is dismantled to accommo-
date the 5-phenyl group. Interestingly, despite the structural
changes that cause loss of the distal water ligand, both com-
plexes are catalytically active and result in processing of the
meso-substituted hemes.
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